Latest Intelligence on Genitourinary and Osteoporosis in Europe

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

HRT: study kicks market when it's down

The UK Million Women study has confirmed that current or recent users of all types of HRT face an increased risk of developing breast cancer. The HRT market is already depressed after the findings of last year's Women's Health Initiative (WHI) in the US. This study is likely to spell the end of long-term HRT use.<BR />

Published By Datamonitor
08 Aug 2003
ResearchWire
ResearchWire

HRT market: innovative treatment options to restore growth

Published By Datamonitor
25 Apr 2008
CommentWire
CommentWire

GlaxoSmithKline: EU approval bodes well for future blockbuster

The European Medicines Agency has approved GlaxoSmithKline's combination therapy Duodart for the treatment of moderate to severe symptoms of benign prostatic hyperplasia and reduction in the risk of acute urinary retention. Duodart's approval paves the way for GlaxoSmithKline to become the leading company in this market, with seven major market annual revenues set to exceed $1.1 billion by 2018.

Published By Datamonitor
31 Mar 2010
Expert View
Expert View

FIGO 2009: focus moves towards cervical cancer and overactive bladder

Among the key developments at this year's International Federation of Gynecology and Obstetrics meeting, pharmaceutical companies aimed to improve awareness of overactive bladder. Elsewhere, the reduction of mortality due to cervical cancer emerged as a key theme among delegates, with discussions of vaccine strategies not only in the developed world but also in developing countries.

Published By Datamonitor
13 Oct 2009
Expert View
Expert View

FIGO 2009: expert backing for HRT for menopausal symptoms is welcome news

The debate regarding the use of HRT in postmenopausal women and its safety was very much a central topic throughout this year's International Federation of Gynecology and Obstetrics conference. Despite market-leader Wyeth's absence from the meeting, the core message that HRT should continue to be given to women in need will benefit players in this market.

Published By Datamonitor
13 Oct 2009
Expert View
Expert View

FIGO 2009: Bayer-Schering maintains leadership in contraception

Datamonitor attended this year's International Federation of Gynecology and Obstetrics World Congress in Cape Town to assess the state of the women's healthcare market. The overwhelming presence of Bayer-Schering at the conference confirms the company's strength in the contraceptives field and its commitment to maintaining its market-leading position.

Published By Datamonitor
13 Oct 2009
CommentWire
CommentWire

Ferring: strong R&D base for next generation incontinence treatment

Ferring's next generation of antidiuretics to treat urinary incontinence could make use of pioneering research by Nobel Laureate Professor Agre. The company's close relationship with academia and its own long history of research in the urinary incontinence field should strengthen its position as a leading urology player.

Published By Datamonitor
01 Mar 2004
Expert View
Expert View

AUA 2010: encouraging new drugs in benign prostatic hyperplasia but challenges remain

Datamonitor attended this year's meeting of the American Urological Association, at which data were presented for two promising new candidates developed for the treatment of benign prostatic hyperplasia. Specifically, Watson Pharmaceuticals outlined the differentiators for its new treatment Rapaflo, while Nymox used the meeting to present new data for its pipeline drug NX-1207.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

AUA 2010: companies aim to maintain presence in lucrative overactive bladder arena

Overactive bladder was a key area of focus at this year's meeting of the American Urological Association. In attending the conference, Datamonitor identified new strategies from Pfizer and Watson Pharmaceuticals which aim to put these companies' drugs at the forefront of treatment in this lucrative disease area.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

Astellas: positive Phase III data bode well for novel overactive bladder candidate

Astellas has presented positive new Phase III data for mirabegron, a drug that treats overactive bladder symptoms. The efficacy and safety profile suggests that the drug is well positioned to address some of the unmet needs in the overactive bladder market, and should cardiovascular safety be established, mirabegron is likely to become a leading treatment option.

Published By Datamonitor
21 Mar 2011

« | 1 | 2 | 3 | 4 | » »|

No help is available.